Dosimetry-based high-activity therapy with 131I-metaiodobenzylguanidine (131I-mIBG) and topotecan for the treatment of high-risk refractory neuroblastoma

被引：0
|
作者：
Jose Genolla
Trinidad Rodriguez
Pablo Minguez
Ricardo Lopez-Almaraz
Veronica Llorens
Aizpea Echebarria
机构：
[1] Cruces University Hospital,Department of Nuclear Medicine
[2] Cruces University Hospital,Department of Medical Physics and Radiation Protection
[3] Cruces University Hospital,Department of Pediatric Oncology and Hematology
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2019年 / 46卷
关键词：
High-risk neuroblastoma; I-mIBG therapy; Topotecan; Dosimetry;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1567 / 1575
页数：8
相关论文
共 50 条
  • [31] High dose dosimetry-guided 131I-MIBG treatment for refractory primary neuroblastoma: a case report
    Boni, G.
    Borso, E.
    Mazzarri, S.
    Menconi, M.
    Casazza, G.
    Favre, C.
    Traino, C. A.
    Mariani, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S532 - S532
  • [32] 131I-Metaiodobenzylguanidine (131I-MIBG) double infusion with autologous stem cell transplant for neuroblastoma:: A New Approaches to Neuroblastoma Therapy (NANT) study.
    Matthay, K. K.
    Quach, A.
    Huberty, J.
    Franc, B.
    Groshen, S.
    Shusterman, S.
    Veatch, J.
    Brophy, P.
    Yanik, G.
    Maris, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 504S - 504S
  • [33] The Optimal Use And Effectiveness Of131I-meta Iodobenzylguanidine (131I-mIBG) Molecular Radiotherapy For High-Risk And Relapsed/Refractory Neuroblastoma
    Plaza de las Heras, I.
    Osuna Marco, M.
    Martin Lopez, L.
    Villa Alcazar, M.
    Field Galan, C.
    Garcia Canamaque, L.
    Lopez Ibor, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S348 - S348
  • [34] THE OPTIMAL USE AND EFFECTIVENESS OF 131I-META IODOBENZYLGUANIDINE (131I-MIBG) MOLECULAR RADIOTHERAPY FOR HIGH-RISK AND RELAPSED/REFRACTORY NEUROBLASTOMA
    Marco, Marta Osuna
    Lopez, Laura Martin
    Plaza De las Heras, Isabel
    Alcazar, Marta Villa
    Lopez-Ibor, Blanca
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S226 - S226
  • [35] Dosimetry for fractionated 131I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results
    Buckley, S.
    Flux, G.
    Gaze, M.
    Chittenden, S.
    Partridge, M.
    Lancaster, D.
    Pearson, A.
    Saran, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 : S339 - S339
  • [36] Dosimetry for fractionated 131I-mIBG therapies in patients with primary resistant high-risk neuroblastoma:: Preliminary results
    Buckley, Susan E.
    Saran, Frank H.
    Gaze, Mark N.
    Chittenden, Sarah
    Partridge, Mike
    Lancaster, Donna
    Pearson, Andrew
    Flux, Glenn D.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2007, 22 (01) : 105 - 112
  • [37] 131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma
    Dubois, S. G.
    Matthay, K. K.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 57 (01): : 53 - 65
  • [38] Individualised 131I-mIBG Therapy in the Management of Refractory and Relapsed Neuroblastoma
    George, S. L.
    Kirk, S. J.
    Lancaster, D.
    Vaidya, S. J.
    Mandeville, H.
    Saran, F.
    Chittenden, S. J.
    Pearson, A. D. J.
    Du, Y.
    Flux, G. D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S244 - S244
  • [39] Dosimetric evidences of 131I-MIBG treatment in High Risk Neuroblastoma in VERITAS protocol
    Saletti, P.
    Olianti, C.
    Tondo, A.
    Simontacchi, G.
    Belli, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S225 - S225
  • [40] Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma
    George, Sally L.
    Falzone, Nadia
    Chittenden, Sarah
    Kirk, Stephanie J.
    Lancaster, Donna
    Vaidya, Sucheta J.
    Mandeville, Henry
    Saran, Frank
    Pearson, Andrew D. J.
    Du, Yong
    Meller, Simon T.
    Denis-Bacelar, Ana M.
    Flux, Glenn D.
    NUCLEAR MEDICINE COMMUNICATIONS, 2016, 37 (05) : 466 - 472
12345